Daan Ellens
Chairman
Mr. Ellens has a PhD in molecular biology from the State University of Utrecht and an MBA from the University of Eindhoven. He joined the pharmaceutical group AKZO-Nobel in 1980. In 1994, he became CEO of RheinBiotech where, thanks to a successful IPO and a 2002 merger with Bema Biotech, he turned the company into a major player in vaccinology. Ellens has his own biotechnology consultancy firm, Elkerim. He is a board member of Zealand Pharma (Denmark), RheinBiotech (Netherlands) and 4-Antibody (Switzerland). Alain Munoz
Independent administrator
Dr. Munoz, cardiologist and anaesthesiologist by training, has over 20 years experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president (VP) and the French pharmaceutical company Fournier as VP of R&D and Business Development, subsequently becoming Senior VP of the Pharmaceutical Division. Under his leadership, numerous drug product registrations were obtained world-wide, generating significant sales (Adenocard®, Plavix®, Lipanthyl®/Tricor™, Esclim®,…). He has an in-depth knowledge of the US and Japanese markets, and has concluded several major licensing deals with world-class partners in the industry. He currently acts as an entrepreneur developing his own projects and an adviser to investors. He is a board member of several biotechnology companies (NYSE Euronext: Vivalis SA, VLS; Novagali Pharma SA, NOVA. Nasdaq OMX: Zealand Pharma A/S, ZEAL). Piet Serrure
Piet Serrure holds a masters degree in Economic Sciences from the University of Antwerp, Belgium and brings more than 20 years of practitioner’s experience in the Private Equity Industry. He started his private equity career at BeneVent in 1985 and later founded the Belgian branch of Parnib (NIB Capital) where he was C.E.O. until September 2001. He then founded Origo Management in 2001 which provided investment banking services to private equity and venture capital firms and Becap Bvba in 2006 which provides specialized consulting services to the private equity and venture capital industry. He was a member of the Board of Directors and of the Executive Committee of the "European Private Equity and Venture Capital Association" (EVCA) and is a past-President of the "Belgian Venturing Association". René Kuijten
Dr René Kuijten joinded LSP in early 2001 as a general partner. He serves or has served on the supervisory boards of KuDOS (UK, acquired by AstraZeneca in 2005), DNage (NL, acquired by Pharming in 2006), OctoPlus (NL), Kreatech (NL), Hybrigenics (F), BMEYE (NL) and Trinity (US) and has led LSP’s investments in Zealand Pharma (DK) and Morphochem (G, acquired by Biovertis in 2005).
René is also a jury member of New Venture, a business plan competition, and a board member of the McKinsey Alumni Association and the Max Geldens Society. He recently was a member of the Royal Dutch Academy of Sciences committee, advising the Dutch government on gene patenting. From 1992-2000, René was a senior manager at McKinsey & Company in Amsterdam, Brussels and Zurich, and co-leader of the European Pharmaceuticals and Health Care Practice. In this capacity, he advised the management boards of several multinational companies on strategy, M&A, performance improvement and restructuring.
René was trained as a Medical Doctor at the University of Utrecht, Harvard Medical School and the Mayo Clinics. He completed his PhD studies at the University of Pennsylvania Cancer Center and published in medical journals as the New England Journal of Medicine and Cancer Research. He has received research awards from the World Health Organization and the International Union Against Cancer, and the Talma Eijkman Prize and the U-Gene Research Award for his scientific endeavors. He obtained his MBA degree from INSEAD in Fontainebleau, France. Arthur Donny StrosbergIndependent administrator
Prior to co-found Hybrigenics, Pr. Strosberg has been an advisor to several major pharmaceutical companies and has been involved in other start up biotechnology companies. Pr. Strosberg is a specialist in the development of screening technologies especially applied to small molecules binding to membrane receptors expressed in bacteria, in yeast and in mammalian cells. Together with his CNRS laboratory which moved successively from the Paris Science faculty to the Pasteur and then the Cochin Institute, he published over 400 peer-reviewed scientific articles. He holds over twenty patents of which more than two-thirds are licensed to pharmaceutical companies. Eric Castaldi Independent administrator
 Eric Castaldi is CFO and a member of the Executive Committee of NicOx SA, an emerging pharmaceutical company listed on Eurolist in Paris, and which is specialized in the research and development of nitric oxide-donating drugs. Eric Castaldi joined NicOx in 1998 and was in charge of the company’s IPO in November 1999 and subsequent financings for a total of €312m, including a public follow-on, Private Investment in Public Equities (PIPE) offerings and a rights issue.
As a graduate in Finance, Accountancy and Administration from the University of Nice, Eric Castaldi started his career as Financial and Cost Accountant from 1986 to 1989 for Cordis Corporation, a US based company specialized in bio-surgical instrumentation. He joined in 1989 through 1997 My Kinda Town plc, a European leisure company, as CFO and COO, and served, after that, Safety Kleen Corporation, a U.S. based environmental waste company as CFO, where he was responsible for operations in France and Belgium. Rémi Delansorne
CEO, Hybrigenics
Rémi DELANSORNE is 48 years old. He holds a veterinary doctorate from “Ecole Nationale Vétérinaire d’Alfort” and a PhD in life sciences from « Université Pierre et Marie Curie » (Paris VI). After a post-doctoral fellowship at the University of Texas Medical School in Houston, he joined the pharmaceutical industry in 1985 in Theramex, where he held several positions in pre-clinical R&D.until the company was integrated into the Merck Group (now Merck-Serono) in 2000. In 2002. Rémi Delansorne became Merck Global Head of Diabetes Research and responsible for the three preclinical sites in France. Then, he joined Hybrigenics in 2004 as Vice-President for R&D and was appointed CEO of the company in September 2005.
|
